

4
Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 59680

Manuscript Type: CASE REPORT

Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature

Yu Zhang, Di Wu, Bo Zhao, Xue-Liang Tian, Tian-Cheng Yao, Feng Li, Wei-Fang Liu, Ai-Ping Shi

Abstract

BACKGROUND

Occult breast cancer (OBC) is a special type of breast cancer presenting as axillary lymph node metastasis with undetectable primary lesions in the breast. Due to its low incidence and unique clinical manifestations, there is a lack of consensus on the

Match Overview

1	Crossref 51 words Hai-ying Wang, Jun-feng Chu, Peng Zhang, Jia-qiang Wang, Zheng Yan, Shu-na Yao, Zhi-hua Yao, Yan-yan Liu. "	2%
2	Internet 17 words crawled on 19-Mar-2020 www.wjgnet.com	1%
3	Internet 16 words crawled on 02-Aug-2020 www.infona.pl	1%
4	Internet 15 words crawled on 27-Oct-2019 f6publishing.blob.core.windows.net	1%

Application of neoadjuvant chemotherapy combined with anlotinib



ALL

IMAGES

VIDEOS

59,500 Results

Any time ▾

Application of neoadjuvant chemotherapy in occult breast ...

https://www.researchgate.net/publication/320208691_Application_of_neoadjuvant...

Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports Article (PDF Available) in *Medicine* 96(40):e8200 · October 2017 with 73 Reads How we measure 'reads'

Frontiers | Anlotinib Combined With Chemoradiotherapy ...

<https://www.frontiersin.org/articles/10.3389/fonc.2020.00995> ▾

Jul 10, 2020 · Objective: The aim of this study was to evaluate the safety and efficacy of **anlotinib combined** with chemoradiotherapy for treating esophageal squamous cell carcinoma (ESCC) using patient-derived xenografts (PDXs). Methods: PDX-bearing mice were randomly divided into five groups, as follows: control group receiving normal saline, the group receiving radiotherapy, the ...

Author: Jingzhen Shi, Jingzhen Shi, Yingjie ... **Publish Year:** 2020

Neoadjuvant plus adjuvant bevacizumab in early breast ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624323>

Background. NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide **neoadjuvant chemotherapy** would improve outcomes in women with operable, HER2-negative **breast cancer** and whether adding **neoadjuvant** plus adjuvant bevacizumab to **neoadjuvant chemotherapy** ...

Cited by: 117 **Author:** Harry D Bear, Gong Tang, Priya Rastogi,...

Publish Year: 2015

Time trends of neoadjuvant chemotherapy for early breast ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.33122>

May 28, 2020 · 1 INTRODUCTION. The understanding of early **breast cancer** (EBC) as a systemic disease that is determined by specific molecular genetic factors was one of the fundamental breakthroughs in **breast cancer** research and constitutes the basis for therapeutic decision-making. 1 Subsequently, adjuvant systemic therapy additional to surgery gained in ...

Author: Fabian Riedel, Ann Sophie Hoffmann... **Publish Year:** 2020

ALL

IMAGES

VIDEOS

45,600 Results

Any time ▾

Frontiers | Anlotinib Combined With Chemoradiotherapy ...

<https://www.frontiersin.org/articles/10.3389/fonc.2020.00995>

Jul 10, 2020 · Objective: The aim of this study was to evaluate the safety and efficacy of **anlotinib combined** with chemoradiotherapy for treating esophageal squamous cell carcinoma (ESCC) using patient-derived xenografts (PDXs). Methods: PDX-bearing mice were randomly divided into five groups, as follows: control group receiving normal saline, the group receiving radiotherapy, the group receiving ...

Author: Jingzhen Shi, Jingzhen Shi, Yingjie Zha... Publish Year: 2020

Application of neoadjuvant chemotherapy in occult breast ...

https://www.researchgate.net/publication/320208691_Application_of_neoadjuvant...

PDF | Rationale: Although rare, **occult breast cancer** (OBC) originates from **breast** tissue. Its primary lesions cannot be identified by clinical... | Find, read and cite all the research you need on ...

Long-term survival of an elderly patient with advanced ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524267>

On one hand, loss of HER2-positive status occurs after **neoadjuvant** therapy in patients with primary HER2-positive **breast cancer**. On the other hand, 3.4% of **breast cancer** patients with HER2-negative tumors before **chemotherapy** changed to HER2-positive afterwards. According to this case, we guess that the alteration in HER2 expression may happen ...

Author: Qingwei Li, Xuejun Xu, Dan Su, Tianshu... Publish Year: 2019

Pressurized intraperitoneal aerosol chemotheprapy after ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960818>

May 21, 2018 · We **report** the first case in the recent and past **literature** of the **application** of pressurized intraperitoneal aerosol **chemotherapy** (PIPAC) as **neoadjuvant** therapy before palliative D2 gastrectomy **combined** with liver metastasectomy performed in a patient who was with primarily diagnosed and underwent surgery for a KT.

Cited by: 3 Author: Maciej Nowacki, Dariusz Grzanka, Wojciec...

Publish Year: 2018

Evaluation of the response of breast cancer patients to ...

<https://www.spandidos-publications.com/10.3892/etm.2019.7353>

Introduction. **Breast cancer**, a malignant tumor type derived from the epithelium of terminal ductal lobules of the **breast**, is a disease that seriously threatens the health of women (1,2). An estimated 1.2 million women suffer from **breast cancer** worldwide, and 500,000 women die from the disease each year (3,4). In recent years, the incidence of **breast cancer** has increased in China (5,6).

Cited by: 2 Author: Baohua Wang, Tian'an Jiang, Min Huang, Ji...

ALL

IMAGES

VIDEOS

45,600 Results

Any time ▾

[Application of neoadjuvant chemotherapy in occult breast ...](#)

https://www.researchgate.net/publication/320208691_Application_of_neoadjuvant...

PDF | Rationale: Although rare, **occult breast cancer** (OBC) originates from **breast** tissue. Its primary lesions cannot be identified by clinical... | Find, read and cite all the research you need on ...

Search Tools

[Turn off Hover Translation](#)

[Frontiers | Anlotinib Combined With Chemoradiotherapy ...](#)

<https://www.frontiersin.org/articles/10.3389/fonc.2020.00995> ▾

Jul 10, 2020 · Objective: The aim of this study was to evaluate the safety and efficacy of **anlotinib combined** with chemoradiotherapy for treating esophageal squamous cell carcinoma (ESCC) using patient-derived xenografts (PDXs). Methods: PDX-bearing mice were randomly divided into five groups, as follows: control group receiving normal saline, the group receiving radiotherapy, the group receiving ...

Author: Jingzhen Shi, Jingzhen Shi, Yingjie Zha... **Publish Year:** 2020

[Pressurized intraperitoneal aerosol chemotheprapy after ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960818>

May 21, 2018 · We **report** the first **case** in the recent and past **literature** of the **application** of pressurized intraperitoneal aerosol **chemotherapy** (PIPAC) as **neoadjuvant** therapy before palliative D2 gastrectomy **combined** with liver metastasectomy performed in a patient who was with primarily diagnosed and underwent surgery for a KT.

Cited by: 3 **Author:** Maciej Nowacki, Dariusz Grzanka, Wojciec...

Publish Year: 2018

[Long-term survival of an elderly patient with advanced ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524267>

On one hand, loss of HER2-positive status occurs after **neoadjuvant** therapy in patients with primary HER2-positive **breast cancer** . On the other hand, 3.4% of **breast cancer** patients with HER2-negative tumors before **chemotherapy** changed to HER2-positive afterwards . According to this **case**, we guess that the alteration in HER2 expression may happen ...

Author: Qingwei Li, Xuejun Xu, Dan Su, Tianshu... **Publish Year:** 2019